Oncometabolite modification of Keap1 links GSTZ1 deficiency with cancer

Weijie Guo, Binhua P. Zhou

Research output: Contribution to journalComment/debate

3 Scopus citations


Metabolic abnormalities are emerging as an active driver to the development, progression and metastasis of various tumors. In the recent issue of the EMBO Journal, Yang and colleagues identified that succinylacetone (SA) could act as an oncometabolite and that accumulation of SA activates the NRF2/IGF1R axis in hepatocellular carcinoma (HCC) development. These discoveries not only yield great insights in the understanding of tumor biology, but also hold significant clinical ramifications, as these findings may pave a new way for the early diagnosis and treatment of HCC.

Original languageEnglish
Pages (from-to)333-334
Number of pages2
JournalGenes and Diseases
Issue number4
StatePublished - Dec 2019

Bibliographical note

Publisher Copyright:
© 2019 Chongqing Medical University

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics(clinical)
  • Cell Biology


Dive into the research topics of 'Oncometabolite modification of Keap1 links GSTZ1 deficiency with cancer'. Together they form a unique fingerprint.

Cite this